文献速递冠心病血脂与心血管预防

替格瑞洛在动脉粥样硬化性心血管病二级预防中的过早停药:JACC综述

Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本文综述了替格瑞洛在动脉粥样硬化性心血管病二级预防中过早停药的发生率、原因及生物学机制。一项纳入4项随机临床试验、66,870例患者的荟萃分析显示,过早停药率为25%,出血是最常见原因,其次为呼吸困难。与对照药相比,替格瑞洛因呼吸困难停药的风险高6.4倍,因出血停药的风险高3.2倍,因任何不良事件停药的风险高59%。

要点

  • 替格瑞洛过早停药率高达25%,出血和呼吸困难是主要原因。
  • 与对照药相比,替格瑞洛因呼吸困难停药风险高6.4倍,因出血停药风险高3.2倍。
  • 了解停药障碍有助于医患共同决策并改善依从性。

核心结论

  • 替格瑞洛过早停药常见,出血和呼吸困难是主要原因,且与对照药相比风险显著增加。

研究设计与样本

  • 对2007年1月至2017年6月间的4项替格瑞洛随机临床试验进行荟萃分析,共纳入66,870例患者,中位随访18个月。

主要发现

  • 过早停用替格瑞洛的发生率为25%。
  • 出血是停药最常见的原因,其次为呼吸困难。
  • 与对照药相比,替格瑞洛因呼吸困难停药的风险高6.4倍,因出血停药的风险高3.2倍,因任何不良事件停药的风险高59%。

临床怎么用

  • 临床应识别出血和呼吸困难等停药原因,以改善替格瑞洛依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Arora S, Shemisa K, Vaduganathan M, et al. Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. J Am Coll Cardiol. 2019. PMID: 31097167. doi:10.1016/j.jacc.2019.03.470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。